Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Barcelona, Spain. 27 March 2025. New study reports that switching patients with chronic wounds to the multi-layered, bordered silicone-coated foam dressing, Mepilex® Border Flex, alongside a clinician educational support programme, resulted in a significant reduction in the number of dressing changes being undertaken and a reduction in dressing-related costs.1
The study, sponsored by Mölnlycke Health Care, and conducted across primary care facilities in Seville, Spain was today presented as an e-poster at the 35th Conference of the European Wound Management Association (EWMA) 2025 in Barcelona, Spain by the principal investigator Dr Andres Roldan Valenzuela, Centro de Salud Mairena del Aljarafe – Cuidad Expo, Seville.
The primary outcome of the study was a statistically significant reduction in the number of dressing changes undertaken, prior to and after the switch from a bordered foam dressing (baseline) to Mepilex® Border Flex; results demonstrated the median number of dressing changes reduced during the study period, from three in a seven-day period to just one.1
Other reported outcomes included:1
Almost all (97%) of the clinicians rated the overall performance of Mepilex® Border Flex to be better than the previously used dressings, while 100% of patients rated Mepilex® Border Flex as ‘good’ to ‘very good’ in terms of overall satisfaction, compared to 65% for the previously used dressings.
Dr Andres Roldan Valenzuela, principal investigator commented “The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.”
For more information, please contact:
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
The study involved 37 adult patients, aged between 30 and 90+ years presenting with wounds that had not reduced in size by >40-50% in the previous month and had been managed with foam dressing (other than Mepilex® Border Flex), for a minimum of four weeks (baseline). Category 2 pressure ulcers (24.3%) and venous leg ulcers (18.9%) were the most common wound types. Patients in the study had Mepilex® Border Flex applied to their wounds for ≥4 weeks, in conjunction with standard of care.
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.
Gothenburg, Sweden. May 02, 2025. The Wound Care Collaborative Community (WCCC) is leading a groundbreaking initiative looking to develop a standardised pre-clinical testing framework for wound dressings.
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.